Library of Congress subjects (96929)
R Medicine (9332)
RM Therapeutics. Pharmacology (227)
Number of items at this level: 227.
A
A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop.
Al-Omar, Hussain Abdulrahman; Almuhsin, Asma Abdulaziz; Almudaiyan, Lolwa Hamad; Al-Najjar, Amal Hassan; Abu Esba, Laila Carolina; Almodaimegh, Hind; Altawil, Esraa S.; Yousef, Consuela Cheriece; Khan, Mansoor Ahmed; Alyahya, Khalid; Alamre, Jehan; Maraiki, Fatma; Espin, Jaime; Tarricone, Rosanna; Kanavos, Panos
picture_as_pdf
HTA246 Improving access to innovative therapies for rare bleeding disorders:evidence from high income countries.
Alani, A. H.; Eaves, K.; Mills, Mackenzie; Kanavos, P.
Researchers on research integrity:a survey of European and American researchers. (2023)
Allum, Nick; Reid, Abigail; Bidoglia, Miriam; Gaskell, George; Aubert-Bonn, Noémie; Buljan, Ivan; Fuglsang, Simon; Horbach, Serge; Kavouras, Panagiotis; Marušić, Ana; Mejlgaard, Niels; Pizzolato, Daniel; Roje, Rea; Tijdink, Joeri; Veltri, Giuseppe
picture_as_pdf
Cost analysis of the treatment of schizophrenia in the UK: a a simulation model comparing olanzapine, risperidone and haloperidol.
Almond, Stephen; O'Donnell, Owen
A new fuzzy reinforcement learning method for effective chemotherapy. (2023)
Alsaadi, Fawaz E.; Yasami, Amirreza; Volos, Christos; Bekiros, Stelios; Jahanshahi, Hadi
picture_as_pdf
High drug prices are not justified by industry’s spending on research and development. (2023)
Angelis, Aris; Polyakov, Roman; Wouters, Olivier J.; Torreele, Els; McKee, Martin
picture_as_pdf
Early health technology assessment during nonalcoholic steatohepatitis drug development:a two-round, cross-country, multicriteria decision analysis.
Angelis, Aris; Thursz, Mark; Ratziu, Vlad; O'Brien, Alistair; Serfaty, Lawrence; Canbay, Ali; Schiefke, Ingolf; Bana e Costa, João C.; Lecomte, Pascal; Kanavos, Panos
picture_as_pdf
Multiple criteria decision analysis for HTA across four EU member states:piloting the Advance Value Framework.
Angelis, Aris; Linch, Mark; Montibeller, Gilberto; Molina Lopez, Maria Teresa; Zawada, Anna; Orzel, Kinga; Arickx, Francis; Espin, Jaime; Kanavos, Panos
picture_as_pdf
Recalibrating health technology assessment methods for cell and gene therapies.
Angelis, Aris; Naci, Huseyin; Hackshaw, Allan
picture_as_pdf
B
Study of mirtazapine for agitated behaviours in dementia (SYMBAD):a randomised, double-blind, placebo-controlled trial.
Banerjee, Sube; High, Juliet; Stirling, Susan; Shepstone, Lee; Swart, Ann Marie; Telling, Tanya; Henderson, Catherine; Ballard, Clive; Bentham, Peter; Burns, Alistair; Farina, Nicolas; Fox, Chris; Francis, Paul; Howard, Robert; Knapp, Martin; Leroi, Iracema; Livingston, Gill; Nilforooshan, Ramin; Nurock, Shirley; O'Brien, John; Price, Annabel; Thomas, Alan J.; Tabet, Naji
picture_as_pdf
Use of adherence monitoring in drug contracts tied to outcomes:put patients first.
Bartholomew, Theodore; Naci, Huseyin; Robertson, Emma; Schmidt, Harald
picture_as_pdf
Valuing Alzheimer's disease drugs:a health technology assessment perspective on outcomes.
Bauer, Annette; Wittenberg, Raphael; Ly, Amanda; Gustavsson, Anders; Bexelius, Christin; Tochel, Claire; Knapp, Martin; Nelson, Mia; Sudlow, Catherine
picture_as_pdf
Hemodynamic changes during physiological and pharmacological stress testing in patients with heart failure:a systematic review and meta-analysis.
Bingel, Anne; Messroghli, Daniel; Weimar, Andreas; Runte, Kilian; Salcher-Konrad, Maximilian; Kelle, Sebastian; Pieske, Burkert; Berger, Felix; Kuehne, Titus; Goubergrits, Leonid; Fuerstenau, Daniel; Kelm, Marcus
picture_as_pdf
Availability of new medicines in the US and Germany from 2004 to 2018.
Blankart, Katharina; Naci, Huseyin; Chandra, Amitabh
picture_as_pdf
Applying the win ratio method in clinical trials of orphan drugs:an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.
Boentert, Matthias; Berger, Kenneth I.; Díaz-Manera, Jordi; Dimachkie, Mazen M.; Hamed, Alaa; Riou França, Lionel; Thibault, Nathan; Shukla, Pragya; Ishak, Jack; Caro, J. Jaime
picture_as_pdf
How to appropriately extrapolate costs and utilities in cost-effectiveness analysis.
Bojke, Laura; Manca, Andrea; Asaria, Miqdad; Mahon, Ronan; Ren, Shijie; Palmer, Stephen
High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial.
Bosch, B.; Sokhela, S.; Akpomiemie, G.; Chandiwana, N.; Venter, W.D.F.; Simmons, Bryony; McCann, K.; Mirchandani, M.; Hill, A.
Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
Brogan, David; Mossialos, Elias
Book review: The bitterest pills: the troubling story of antipsychotic drugs by Joanna Moncrieff.
Brown, Sally
Modelling the treated course of schizophrenia: development of a discrete event simulation model.
Buskens, Erik; Heeg, Bart M; Knapp, Martin; van Aalast, Gerda; Dries, Pieter J T; de Haan, Lieuwe; van Hout, Ben A
Valuing knowledge of the cost and cost-effectiveness of medicines:commentary on... awareness of the cost of psychotropic medication among doctors.
Byford, Sarah; Mosweu, Iris
C
Creating contexts for effective home-based care of people living with HIV/AIDS. (2004)
Campbell, Catherine; Foulis, C.
Rapid diagnostic tests for dengue would reduce hospitalizations, healthcare costs and antibiotic prescriptions in Spain:a cost-effectiveness analysis. (2023)
Camprubí-Ferrer, Daniel; Ramponi, Francesco; Balerdi-Sarasola, Leire; Godoy, Ana; Sicuri, Elisa; Muñoz, José
picture_as_pdf
Combining cash transfers and cognitive behavioral therapy to reduce antisocial behavior in young men:a mediation analysis of a randomized controlled trial in Liberia. (2023)
Carpena, Marina Xavier; Paula, Cristiane Silvestre; De Mola, Christian Loret; Hessel, Philipp; Avendano, Mauricio; Evans-Lacko, Sara; Matijasevich, Alicia
picture_as_pdf
PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process.
Chavez, D.; Tolkmitt, F.; Mills, M.; Kanavos, P.
Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. (2022)
Cherla, Avi; Mossialos, Elias; Salcher-Konrad, Maximilian; Kesselheim, Aaron S.; Naci, Huseyin
picture_as_pdf
The coverage in England of US-approved cancer drugs reply:in reply.
Cherla, Avi; Naci, Huseyin; Mossialos, Elias
Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities. (2022)
Chisholm, Orin; Sharry, Patrick; Phillips, Lawrence
picture_as_pdf
Cost-effectiveness of community-based distribution of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria, and the Democratic Republic of Congo. (2023)
Cirera, Laia; Sacoor, Charfudin; Meremikwu, Martin; Ranaivo, Louise; Manun'ebo, Manu F.; Pons-Duran, Clara; Arikpo, Dachi; Ramirez, Maximo; Ramponi, Francesco; Figueroa-Romero, Antia; Gonzalez, Raquel; Maly, Christina; Roman, Elaine; Sicuri, Elisa; Pagnoni, Franco; Menéndez, Clara
picture_as_pdf
HTA18 First to launch, first to falter?:an investigation into the clinical benefits and HTA outcomes for first-in-class drugs.
Civitelli, D.; Politopoulou, K.; Mills, Mackenzie; Kanavos, P.
Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias:the GREAT RCT.
Clare, Linda; Kudlicka, Aleksandra; Oyebode, Jan R.; Jones, Roy W.; Bayer, Antony; Leroi, Iracema; Kopelman, Michael; James, Ian A.; Culverwell, Alison; Pool, Jackie; Brand, Andrew; Henderson, Catherine; Hoare, Zoe; Knapp, Martin; Morgan-Trimmer, Sarah; Burns, Alistair; Corbett, Anne; Whitaker, Rhiannon; Woods, Bob
From here to I.A.P.T? (improving access to psychological therapies), preview for a new deal for dynamic psychotherapies:the psychoanalyst as street-level bureaucrat.
Clarke, Jeremy
picture_as_pdf
A new deal for dynamic psychotherapies:the psychoanalyst as street‐level bureaucrat.
Clarke, Jeremy
picture_as_pdf
The digital future beyond the pill.
Cornford, Tony
Pharmacy interventions on COVID-19 in Europe:mapping current practices and a scoping review. (2022)
Costa, Suzete; Romão, Mariana; Mendes, Maria; Horta, Maria Rute; Rodrigues, António Teixeira; Carneiro, António Vaz; Martins, Ana Paula; Mallarini, Erika; Naci, Huseyin; Babar, Zaheer Ud Din
picture_as_pdf
Pharmaceutical policy reform in Spain.
Costa-Font, Joan; McDaid, David
Parallel trade in medicinal drugs is putting the welfare of EU patients at risk.
Costa-i-Font, Joan
The war over drugs: what’s at stake?
Coulter, Steve
D
Cost-utility of attachment-based compassion therapy (ABCT) and Mindfulness-Based Stress Reduction (MBSR) in the management of depressive, anxious, and adjustment disorders in mental health settings:economic evaluation alongside a randomized controlled trial.
D'Amico, Francesco; Navarrete, Jaime; Montero-Marín, Jesús; Cardeñosa-Valera, Eugenia; Navarro-Gil, Mayte; Pérez-Aranda, Adrián; López-del-Hoyo, Yolanda; Collado-Navarro, Carlos; García-Campayo, Javier; Luciano, Juan V.
picture_as_pdf
Communication of anticancer drug benefits and related uncertainties to patients and clinicians:document analysis of regulated information on prescription drugs in Europe. (2023)
Davis, Courtney; Wagner, Anita K.; Salcher-Konrad, Maximilian; Scowcroft, Henry; Mintzes, Barbara; Pokorny, Adrian M J; Lew, Jianhui; Naci, Huseyin
picture_as_pdf
Book review:the politics of weight: feminist dichotomies of power in dieting by Amelia Morris.
Dean, Megan
picture_as_pdf
Allergen immunotherapy for allergic asthma:A systematic review and meta-analysis.
Dhami, S.; Kakourou, A.; Asamoah, F.; Agache, I.; Lau, S.; Jutel, M.; Muraro, A.; Roberts, G.; Akdis, C. A.; Bonini, M.; Cavkaytar, O.; Flood, B.; Gajdanowicz, P.; Izuhara, K.; Kalayci; Mosges, R.; Palomares, O.; Pfaar, O.; Smolinska, S.; Sokolowska, M.; Asaria, M.; Netuveli, G.; Zaman, H.; Akhlaq, A.; Sheikh, A.
Allergen immunotherapy for insect venom allergy:a systematic review and meta-analysis.
Dhami, S.; Zaman, H.; Varga, E. M.; Sturm, G. J.; Muraro, A.; Akdis, C. A.; Antolín-Amérigo, D.; Bilò, M. B.; Bokanovic, D.; Calderon, M. A.; Cichocka-Jarosz, E.; Oude Elberink, J. N.G.; Gawlik, R.; Jakob, T.; Kosnik, M.; Lange, J.; Mingomataj, E.; Mitsias, D. I.; Mosbech, H.; Ollert, M.; Pfaar, O.; Pitsios, C.; Pravettoni, V.; Roberts, G.; Ruëff, F.; Sin, B. A.; Asaria, M.; Netuveli, G.; Sheikh, A.
$1 million for a drug used once.
Dickson, Jane
Enduring and emerging challenges of informed consent.
Dickson, Jane
Personalized medicine: a podcast.
Dickson, Jane
Stratified medicine in 2015 – Leeds Christmas lecture.
Dickson, Jane
Vocal biomarkers: diagnostics through human voice.
Dickson, Jane
Warfarin history timeline.
Dickson, Jane
A decision support tool for warfarin prescribing.
Dickson, Jane
Moving from traditional to more advanced treatments in stroke care is cost-effective:a case study from Greece.
Dimitriadis, Konstantinos; Kyriopoulos, Ilias; Tsivgoulis, Georgios; Vemmos, Konstantinos; Kunz, Wolfgang G.; Mossialos, Elias
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.
Duggan, Andy; Warner, Juliet; Knapp, Martin; Kerwin, Robert
F
Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. (2023)
Feldman, William B.; Tu, S. Sean; Alhiary, Rasha; Kesselheim, Aaron S.; Wouters, Olivier J.
picture_as_pdf
Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study).
Feliu-Soler, Albert; Borràs, Xavier; Peñarrubia-María, María T.; Rozadilla-Sacanell, Antoni; D’Amico, Francesco; Moss-Morris, Rona; Howard, Matthew A.; Fayed, Nicolás; Soriano-Mas, Carles; Puebla-Guedea, Marta; Serrano-Blanco, Antoni; Pérez-Aranda, Adrián; Tuccillo, Raffaele; Luciano, Juan V.
Evaluation of the cost effectiveness of Escitalopram versus Venlafaxine XR in major depressive disorder.
Fernández, José-Luis; Montgomery, Stuart; Francois, Clément
Perspectives in the study of the political economy of COVID-19 vaccine regulation. (2022)
Fonseca, Elize M.da; Jarman, Holly; King, Elizabeth J.; Greer, Scott L.
picture_as_pdf
Market access for medicines treating rare diseases:association between specialised processes for orphan medicines and funding recommendations. (2022)
Fontrier, Anna-Maria
picture_as_pdf
Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community. (2024)
Forlano, Roberta; Stanic, Tijana; Jayawardana, Sahan; Mullish, Benjamin H.; Yee, Michael; Mossialos, Elias; Goldin, Robert D.; Petta, Salvatore; Tsochatzis, Emmanouil; Thursz, Mark R.; Manousou, Pinelopi
picture_as_pdf
The size of the US pharmaceutical market means that the US Food and Drug Administration has a disproportionately large global influence.
Forrest, Robin
picture_as_pdf
Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018.
Fu, Mengyuan; Naci, Huseyin; Booth, Christopher M.; Gyawali, Bishal; Cosgrove, Austin; Toh, Sengwee; Xu, Ziyue; Guan, Xiaodong; Ross-Degnan, Dennis; Wagner, Anita K.
G
Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia.
Gallego, Ana; Serrat, Mayte; Royuela-Colomer, Estíbaliz; Sanabria-Mazo, Juan P.; Borràs, Xavier; Esteve, Montserrat; Grasa, Mar; Rosa, Araceli; Rozadilla-Sacanell, Antoni; Almirall, Miriam; D'Amico, Francesco; Dai, Yifei; Rosenbluth, Michael J.; McCracken, Lance M.; Navarrete, Jaime; Feliu-Soler, Albert; Luciano, Juan V.
picture_as_pdf
Trusting the results of model-based economic analyses: is there a pragmatic validation solution?
Ghabri, Salah; Stevenson, Matt; Möller, Jörgen; Caro, J. Jaime
picture_as_pdf
RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap.
Gill, Jennifer; Kanavos, Panos; d'Angela, Daniela; Berger, Karin; Dank, Magdolna; Duncombe, Robert; Fink-Wagner, Antje; Hutton, John; Kossler, Ingrid; Podrazilova, Katerina; Thomas, Michael
MSR1 Estimating lifetime benefits of optimizing secondary preventive treatment for atherosclerotic cardiovascular disease.
Gill, Jennifer L; Miracolo, Aurelio; Politopoulou, Konstantina; Jayawardana, Sahan; Apostolou, Efstratios A.; Carter, Alex; Kanavos, Panos
Projections of future burden of pharmacologically treated type 2 diabetes and associated life expectancies by income in Finland:a multi-state modeling study.
Guzman-Castillo, Maria; Korhonen, Kaarina; Murphy, Michael; Martikainen, Pekka
picture_as_pdf
Challenges in diabetes mellitus type 2 management in Nepal: a literature review.
Gyawali, Bishal; Ferrario, Alessandra; van Teijlingen, Edwin; Kallestrup, Per
H
Patients’ experiences treated with open-label placebo versus double-blind placebo:a mixed methods qualitative study. (2022)
Haas, Julia W.; Ongaro, Giulio; Jacobson, Eric; Conboy, Lisa A.; Nee, Judy; Iturrino, Johanna; Rangan, Vikram; Lembo, Anthony; Kaptchuk, Ted J.; Ballou, Sarah
picture_as_pdf
Rhetoric vs reality: contraception in India and the DMPA debate.
Hamilton, Zoe; Munger, Anne
Physician antipsychotic overprescribing letters and cognitive, behavioral, and physical health outcomes among people with dementia:a secondary analysis of a randomized clinical trial. (2024)
Harnisch, Michelle; Barnett, Michael l.; Coussens, Stephen; Thomas, Kali s.; Olfson, Mark; Berhane, Kiros; Sacarny, Adam
picture_as_pdf
Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público.
Helfer, Ana Paula; Camargo, Aline Lins; Tavares, Noemia Urruth Leão; Kanavos, Panos; Bertoldi, Andréa Dâmaso
Cost-effectiveness of an online intervention for caregivers of people living with dementia. (2022)
Henderson, Catherine; Knapp, Martin; Fossey, Jane; Frangou, Elena; Ballard, Clive
picture_as_pdf
Cost-effectiveness of mirtazapine for agitated behaviors in dementia:findings from a randomized controlled trial. (2022)
Henderson, Catherine; Knapp, Martin; Stirling, Susan; Shepstone, Lee; High, Juliet; Ballard, Clive; Bentham, Peter; Burns, Alistair; Farina, Nicolas; Fox, Chris; Fountain, Julia; Francis, Paul; Howard, Robert; Leroi, Iracema; Livingston, Gill; Nilforooshan, Ramin; Nurock, Shirley; O’brien, John T.; Price, Annabel; Swart, Ann Marie; Tabet, Naji; Telling, Tanya; Thomas, Alan J.; Banerjee, Sube
picture_as_pdf
Net prices of new antiobesity medications.
Hernandez, Inmaculada; Sullivan, Sean D.
Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives. (2024)
Hernandez, Inmaculada; Cousin, Emma M.; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D.
picture_as_pdf
Accelerating access to new drugs in Japan.
Hibberd, Ralph
Brexit and the falsified medicines directive.
Hibberd, Ralph
Combating falsified medicines in Africa through digital artefacts.
Hibberd, Ralph
Hub and spoke dispensing: privacy and sociotechnical rigidity.
Hibberd, Ralph
Hub and spoke dispensing: safety and sociotechnical pliability.
Hibberd, Ralph
Low CD4 counts predict excessive weight gains during first-line treatment for HIV.
Hill, Andrew; Tovar sanchez, Tamara; Delaporte, Eric; Sokhela, Simiso; Simmons, Bryony; Kouanfack, Charles; Mccann, Kaitlyn; Levi, Jacob; Fairhead, Cassandra; Venter, Francois
picture_as_pdf
A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong, Jihyung; Dilla, Tatiana; Arellano, Jorge
J
Global consumption patterns of combination hypertension medication:an analysis of pharmaceutical sales data from 2010–2021.
Jayawardana, Sahan; Campbell, Allen; Aitken, Murray; Andersson, Charlotte E.; Mehra, Mandeep R.; Mossialos, Elias
picture_as_pdf
Global consumption of prescription opioid analgesics between 2009-2019:a country-level observational study. (2021)
Jayawardana, Sahan; Forman, Rebecca; Johnston-Webber, Charlotte; Campbell, Allen; Berterame, Stefano; de Joncheere, Cees; Aitken, Murray; Mossialos, Elias
picture_as_pdf
Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland:a retrospective, comparative analysis. (2024)
Jenei, Kristina; Gentilini, Arianna; Haslam, Alyson; Prasad, Vinay
picture_as_pdf
Characteristics of clinician input in Canadian funding decisions for cancer drugs:a cross-sectional study based on CADTH reimbursement recommendations.
Jenei, Kristina; Meyers, Daniel
picture_as_pdf
The price effects of biosimilars in the United States.
Jofre-Bonet, Mireia; McGuire, Alistair; Dayer, Victoria; Roth, Joshua A; Sullivan, Sean D
The impact of generic entry of pharmaceuticals in Australia.
Jones, Arun M.; Serra-Sastre, Victoria; Kim, Hansoo
picture_as_pdf
Sodium nitrite–mediated cardioprotection in primary percutaneous coronary intervention for ST-Segment Elevation Myocardial Infarction:a cost-effectiveness analysis.
Jones, Daniel A.; Whittaker, Peter; Rathod, Krishnaraj S.; Richards, Amy J.; Andiapen, Mervyn; Antoniou, Sotiris; Mathur, Anthony; Ahluwalia, Amrita
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease: a multicentre RCT.
Jones, Rob; Sheehan, Bart; Phillips, Patrick; Knapp, Martin
Droplet microfluidics platform for highly sensitive and quantitative detection of malaria-causing plasmodium parasites based on enzyme activity measurement.
Juul, Sissel; Nielsen, Christine J. F.; Labouriau, Rodrigo; Roy, Amit; Tesauro, Cinzia; Jensen, Pia W.; Harmsen, Charlotte; Kristoffersen, Emil L.; Chiu, Ya-Ling; Frøhlich, Rikke; Fiorani, Paola; Cox-Singh, Janet; Tordrup, David; Koch, Jørn; Bienvenu, Anne-Lise; Desideri, Alessandro; Picot, Stephane; Petersen, Eskild; Leong, Kam W.; Ho, Yi-Ping; Stougaard, Magnus; Knudsen, Birgitta R.
K
Financing pharmaceuticals in transition.
Kanavos, Panos
Competition in off-patent drug markets: issues, regulation and evidence.
Kanavos, Panos; Costa-i-Font, Joan; Seeley, Elizabeth
Pharmaceutical pricing and reimbursement in Europe.
Kanavos, Panos; Gemmill, Marin
Drugs US: are prices too high?: measuring international pharmaceutical price differences.
Kanavos, Panos; Vandoros, Sotiris
Trade agreements, patents, and drug prices: continuing the debate.
Kapczynski, Amy; Sampat, Bhaven N.; Shadlen, Kenneth C.
App-based food-specific inhibitory control training as an adjunct to treatment as usual in binge-type eating disorders:a feasibility trial. (2022)
Keeler, Johanna Louise; Chami, Rayane; Cardi, Valentina; Hodsoll, John; Bonin, Eva; MacDonald, Pamela; Treasure, Janet; Lawrence, Natalia
picture_as_pdf
Pirates and property:the moralities of branded and generic medicines.
Keeyaa, Chaurey
picture_as_pdf
Comparative effectiveness and safety of concomitant treatment with Chuna Manual Therapy and usual care for whiplash injuries:a multicenter randomized controlled trial.
Kim, Byung-Jun; Park, A-La; Hwang, Man-Suk; Heo, In; Park, Sun-Young; Cho, Jae-Heung; Kim, Koh-Woon; Lee, Jun-Hwan; Ha, In-Hyuk; Park, Kyoung-Sun; Hwang, Eui-Hyoung; Shin, Byung-Cheul
picture_as_pdf
Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
King, Derek; Knapp, Martin; Thomas, P.; Razzouk, D.; Loze, J.-Y.; Kan, H.J.; van Baardewijk, M.
Non-adherence to antipsychotic medication regimens: associations with resource use and costs.
Knapp, Martin; King, Derek; Pugner, Klaus; Lapuerta, Pablo
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.
Knapp, Martin; Locklear, Julie; Jarbrink, Krister
Recovery and economics.
Knapp, Martin; McDaid, David; Park, A-La
Underuse of medication for circulatory disorders among unmarried women and men in Norway?
Kravdal, Øystein; Grundy, Emily
Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland.
Kwong, Danica; Ferrario, Alessandra; Adamski, Jajub; Inotai, Andras; Kalo, Zoltan
L
Afterword.
Le Grand, Julian
The effect of prescription drug insurance on the incidence of potentially inappropriate prescribing:evidence from Medicare Part D.
Lee, Donghoon; Kim, SangJune; Dugan, Jerome A.
picture_as_pdf
The 30-billion-dollar distribution markups and taxes of pharmaceuticals in Latin American countries:impact, options, and trade-offs.
Leon, Giovanny; Gonzalez-Pier, Eduardo; Kanavos, Panos; Ruiz de Castilla, Eva Maria; Machinicki, Gerardo
picture_as_pdf
New deviancy theory and the healthcare system's role in creating, labeling, and facilitating unauthorized prescription drug “abuse”.
Levin, David; Shiner, Michael
Optimisation-based modelling for explainable lead discovery in malaria.
Li, Yutong; Cardoso-Silva, Jonathan; Kelly, John M.; Delves, Michael J.; Furnham, Nicholas; Papageorgiou, Lazaros G.; Tsoka, Sophia
picture_as_pdf
‘the little liar’ – patient information about medicines.
Lichtner, Valentina
Correction to:which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease.
Lomas, James; Asaria, Miqdad; Bojke, Laura; Gale, Chris P.; Richardson, Gerry; Walker, Simon
picture_as_pdf
Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie.
Luyten, Jeroen; McKee, Martin; Wouters, Olivier J.
picture_as_pdf
M
From vision to reality:the EU's pharmaceutical reforms and the path to improved access.
Main, Caitlin; Schafer, Cathrin; Kanavos, Panos
picture_as_pdf
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström, Rickard E.; Godman, Brian B.; Diogene, Eduard; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Brzezinska, Anna; Bucsics, Anna; Campbell, Stephen; Ferrario, Alessandra; Finlayson, Alexander E.; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Gutiérrez-Ibarluzea, Iñaki; Haycox, Alan; Hviding, Krystyna; Herholz, Harald; Hoffmann, Mikael; Jan, Saira; Jones, Jan; Joppi, Roberta; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Langner, Irene; Lonsdale, Julie; Lööv, Sven-Äke; Malinowska, Kamila; McCullagh, Laura; Paterson, Ken; Markovic-Pekovic, Vanda; Martin, Andrew; Piessnegger, Jutta; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tulunay, Cankat; Tomek, Dominik; Vončina, Luka; Vlahovic-Palcevski, Vera; Wale, Janet; Wilcock, Michael; Wladysiuk, Magdalena; Woerkom, Menno van; Zara, Corrine; Gustafsson, Lars L.
A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients.
Manfrin, Andrea; Tinelli, Michela; Thomas, Trudy; Krska, Janet
Improving access to medicines:lessons from 10 years of drug reforms in China, 2009-2020. (2022)
Mao, Wenhui; Jiang, Hongli; Mossialos, Elias; Chen, Wen
picture_as_pdf
Are large prospective trials on antidepressants in mental disorders seeding trials?:a descriptive study of trials registered on ClinicalTrials.gov.
Martineau, Samuel; Cristea, Ioana-Alina; Chevance, Astrid; Fanelli, Daniele; Naudet, Florian
picture_as_pdf
Brazil’s fight against Hepatitis C:universalism, local production, and patents.
Massard da Fonseca, Elize; Shadlen, Kenneth C.; Inácio Bastos, Francisco
picture_as_pdf
IMPACT smoking cessation support for people with severe mental illness in South Asia (IMPACT 4S):a protocol for a randomised controlled feasibility trial of a combined behavioural and pharmacological support intervention. (2023)
Mazumdar, Papiya; Zavala, Gerardo; Aslam, Faiza; Muliyala, Krishna Prasad; Chaturvedi, Santosh Kumar; Kandasamy, Arun; Nizami, Asad; Ul Haq, Baha; Kellar, Ian; Jackson, Cath; Thomson, Heather; McDaid, David; Siddiqi, Kamran; Hewitt, Catherine; Siddiqi, Najma; Gilbody, Simon; Murthy, Pratima; Dadirai Mdege, Noreen
picture_as_pdf
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
McCrone, Paul R.; Chisholm, Daniel; Knapp, Martin; Hughes, Richard; Comi, Giancarlo; Dalakas, Marinos C.; Illa, Isabel; Kilindireas, Costas; Nobile-Orazio, Eduardo; Swan, Anthony Victor; Van den Bergh, Peter; Willison, Hugh J.
Cost-effectiveness of individual versus group psychotherapy for sexually abused girls.
McCrone, Paul R.; Weeramanthri, Tara; Knapp, Martin R.J.; Rushton, Alan; Trowell, Judith; Miles, Gillian; Kolvin, Israel
The European value-pricing game.
McGuire, Alistair
Overview of the Arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.
McGuire, Alistair; Burke, T.; Goldstein, J.; Maniadakis, N.; Pettitt, D.
640P Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials.
Michaeli, D. T.; Michaeli, J. C.; Mossialos, E.; Albers, S.; Michaeli, C. T.
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. (2022)
Michaeli, Daniel Tobias; Mills, Mackenzie; Michaeli, Thomas; Miracolo, Aurelio; Kanavos, Panos
picture_as_pdf
Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa. (2022)
Michaeli, Daniel Tobias; Stoycheva, Sophia; Marcus, Simon Mashudu; Zhang, Wenjia; Michaeli, Julia Caroline; Michaeli, Thomas
picture_as_pdf
Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products:evidence from nine OECD countries. (2023)
Mills, Mackenzie; Kanavos, Panos
picture_as_pdf
HTA barriers for conditional approval drugs. (2023)
Mills, Mackenzie
picture_as_pdf
Using international human rights law to guarantee the right to health: a Brazilian experience.
Morais de Oliveira, Iago
N
The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges.
Naci, Huseyin
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16:cross-sectional analysis.
Naci, Huseyin; Davis, Courtney; Savović, Jelena; Higgins, Julian P. T.; Sterne, Jonathan; Gyawali, Bishal; Romo Sandoval, Xochitl Citlalli; Handley, Nicola; Booth, Christopher M
picture_as_pdf
Characteristics of prior authorization policies for new drugs in Medicare Part D. (2023)
Naci, Huseyin; Forrest, Robin; Zhai, Mike; Stofesky, Amanda R.; Kesselheim, Aaron S.
picture_as_pdf
Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs.
Naci, Huseyin; Guan, Xiaodong; Woloshin, Steven; Xu, Ziyue; Wagner, Anita K.
picture_as_pdf
Producing and using timely comparative evidence on drugs:lessons from clinical trials for covid-19.
Naci, Huseyin; Kesselheim, Aaron S.; Rttingen, John Arne; Salanti, Georgia; Vandvik, Per O.; Cipriani, Andrea
description
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20:a retrospective analysis.
Naci, Huseyin; Murphy, Peter; Woods, Beth; Lomas, James; Wei, Jinru; Papanicolas, Irene
picture_as_pdf
How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. (2018)
Naci, Huseyin; Salcher-Konrad, Maximilian; Dias, Sofia; Blum, Manuel R.; Sahoo, Samali Anova; Nunan, David; Ioannidis, John P. A.
picture_as_pdf
Impact of predictive medicine on therapeutic decision making:a randomized controlled trial in congenital heart disease.
Naci, Huseyin; Salcher-Konrad, Maximilian; Mcguire, Alistair; Berger, Felix; Kuehne, Titus; Goubergrits, Leonid; Muthurangu, Vivek; Wilson, Ben; Kelm, Marcus
picture_as_pdf
Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs.
Naci, Huseyin; van Valkenhoef, G.; Higgins, J. P. T.; Fleurence, R.; Ades, A. E.
Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB):protocol for a randomised controlled trial. (2024)
Namale, Phiona E.; Boloko, Linda; Vermeulen, Marcia; Haigh, Kate A.; Bagula, Fortuna; Maseko, Alexis; Sossen, Bianca; Lee-Jones, Scott; Msomi, Yoliswa; McIlleron, Helen; Mnguni, Ayanda Trevor; Crede, Thomas; Szymanski, Patryk; Naude, Jonathan; Ebrahim, Sakeena; Vallie, Yakoob; Moosa, Muhammed Shiraz; Bandeker, Ismail; Hoosain, Shakeel; Nicol, Mark P.; Samodien, Nazlee; Centner, Chad; Dowling, Wentzel; Denti, Paolo; Gumedze, Freedom; Little, Francesca; Parker, Arifa; Price, Brendon; Schietekat, Denzil; Simmons, Bryony; Hill, Andrew; Wilkinson, Robert J.; Oliphant, Ida; Hlungulu, Siphokazi; Apolisi, Ivy; Toleni, Monica; Asare, Zimkhitha; Mpalali, Mkanyiseli Kenneth; Boshoff, Erica; Prinsloo, Denise; Lakay, Francisco; Bekiswa, Abulele; Jackson, Amanda; Barnes, Ashleigh; Johnson, Ryan; Wasserman, Sean; Maartens, Gary; Barr, David; Schutz, Charlotte; Meintjes, Graeme
picture_as_pdf
Generic cardiology drug prices:the potential benefits of the Marc Cuban cost plus drug company model.
Narendrula, Aparna; Lang, Jacob; Mossialos, Elias
picture_as_pdf
Snake oil or super drug:how have regulators and payers perceived new medicines that target asymptomatic conditions?
Needham, Brian Richard
picture_as_pdf
European Medicines Agency’s Priority Medicines scheme at 2 years:an evaluation of clinical studies supporting eligible drugs.
Neez, Emilie Marie Celine Anne; Hwang, Thomas; Sahoo, Samali Anova; Naci, Huseyin
picture_as_pdf
COVID-19 vaccination personas in Syria:evidence from a cross-sectional survey.
Nikoloski, Zlatko; Aliyev, Elnur; Bain, Robert E.S.; Menchini, Leonardo; Hegazi, Sahar; Zalkha, Mai; Mouawad, Shaza; Kapil, Neha; Gillespie, Amaya M.
picture_as_pdf
COVID-19 vaccination personas in Yemen:insights from three rounds of a cross-sectional survey.
Nikoloski, Zlatko; Chimenya, Dennis; Alshehari, Abdullah; Hassan, Hauwa; Bain, Robert; Menchini, Leonardo; Gillespie, Amaya
picture_as_pdf
Cost-effectiveness analysis of filgotinib versus tofacitinib as first-line treatments for rheumatoid arthritis in Greece.
Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
EE477 A budget impact analysis of introducing filgotinib for the treatment of rheumatoid arthritis in Greece.
Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
EE478 A budget impact analysis of introducing filgotinib as a first-line treatment for moderate to severe ulcerative colitis in Greece.
Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece.
Nomikos, N.; Naoum, P.; Athanasakis, Kostas; Kyriopoulos, I
So near yet so far:why won't the UK prescribe medical cannabis? (2020)
Nutt, David; Bazire, Steve; Phillips, Lawrence D.; Schlag, Anne Katrin
picture_as_pdf
A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. (2022)
Nutt, David J.; Phillips, Lawrence D.; Barnes, Michael; Brander, Brigitta; Curran, H. Valerie; Fayaz, Alan; Finn, David P.; Horsted, Tina; Moltke, Julie; Sakal, Chloe; Sharon, Haggai; O’Sullivan, Saoirse; Williams, Tim; Zorn, Gregor; Schlag, Anne Katrin
picture_as_pdf
P
Understanding decisions about antibiotic prescribing in ICU:an application of the Necessity Concerns Framework. (2022)
Pandolfo, Alyssa M.; Horne, Robert; Jani, Yogini; Reader, Tom W.; Bidad, Natalie; Brealey, David; Enne, Virve I.; Livermore, David M.; Gant, Vanya; Brett, Stephen J.
picture_as_pdf
Economic modelling of mindfulness meditation for people with mental health problems.
Park, A-La; McDaid, David
The use of complementary and alternative medicine by adults with allergies:a Czech national representative survey. (2021)
Pokladnikova, Jitka; Park, A-La; Draessler, Jan; Lukacisinova, Anna; Krcmova, Irena
picture_as_pdf
HTA255 First-in-class drugs in HTA:blunder or bliss?
Politopoulou, Konstantina; Mills, Mackenzie; Kanavos, Panos
R
What should we do about student use of cognitive enhancers?: an analysis of current evidence.
Ragan, C. Ian; Bard, Imre; Singh, Ilina
Sensory integration therapy versus usual care for sensory processing difficulties in autism spectrum disorder in children:study protocol for a pragmatic randomised controlled trial.
Randell, Elizabeth; McNamara, Rachel; Delport, Sue; Busse, Monica; Hastings, Richard P.; Gillespie, David; Williams-Thomas, Rhys; Brookes-Howell, Lucy; Romeo, Renee; Boadu, Janet; Ahuja, Alka S.; McKigney, Anne Marie; Knapp, Martin; Smith, Kathryn; Thornton, Jacqui; Warren, Gemma
A new approach to formulating and appraising drug policy: a multi-criterion decision analysis applied to alcohol and cannabis regulation.
Rogeberg, Ole; Bergsvik, Daniel; Phillips, Lawrence D.; Amsterdam, Jan van; Eastwood, Niamh; Henderson, Graeme; Lynskey, Michael; Measham, Fiona; Ponton, Rhys; Rolles, Steve; Schlag, Anne Katrin; Taylor, Polly; Nutt, David
Defining a framework for sustainable global biosimilars markets using findings from a targeted literature review. (2025)
Roth, Joshua A; Dayer, Victoria W.; Jofre-Bonet, Mireia; McGuire, Alistair; Sullivan, Sean D.
S
Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
Sado, Mitsuhiro; Knapp, Martin; Yamauchi, Keita; Fujisawa, Daisuke; So, Mirai; Nakagawa, Atsuo; Kikuchi, Toshiaki; Ono, Yutaka
Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines.
Salas-Vega, Sebastian; Iliopoulos, Othon; Mossialos, Elias
Treatment effects in randomized and nonrandomized studies of pharmacological interventions:a meta-analysis.
Salcher-Konrad, Maximilian; Nguyen, Mary; Savović, Jelena; Higgins, Julian P. T.; Naci, Huseyin
picture_as_pdf
Prescriber commitment posters to increase prudent antibiotic prescribing in English general practice:a cluster randomized controlled trial.
Sallis, Anna; Bondaronek, Paulina; Sanders, Jet G.; Yu, Ly Mee; Harris, Victoria; Vlaev, Ivo; Sanders, Michael; Tonkin-Crine, Sarah; Chadborn, Tim
picture_as_pdf
Economic evaluation of videoconference group Acceptance and Commitment Therapy and Behavioral Activation Therapy for depression versus usual care among adults with chronic low back pain plus comorbid depressive symptoms.
Sanabria-Mazo, Juan P.; D'Amico, Francesco; Cardeñosa, Eugenia; Ferrer-Forés, Monserrat; Edo, Sílvia; Borràs, Xavier; McCracken, Lance M.; Feliu-Soler, Albert; Sanz, Antoni; Luciano, Juan V.
picture_as_pdf
The value of real world evidence:the case of medical cannabis. (2022)
Schlag, Anne Katrin; Zafar, Rayyan R.; Lynskey, Michael T.; Athanasiou-Fragkouli, Alkyoni; Phillips, Lawrence D.; Nutt, David J.
picture_as_pdf
Does NICE influence the adoption and uptake of generics in the UK?
Serra-Sastre, Victoria; Bianchi, Simona; Mestre-Ferrandiz, Jorge; O’Neill, Phill
picture_as_pdf
Accelerating pooled licensing of medicines to enhance global production and equitable access. (2022)
Shadlen, Kenneth C.
Learning from India? A new approach to secondary pharmaceutical patents.
Shadlen, Kenneth C.
picture_as_pdf
Drug patenting in India:looking back and looking forward.
Shadlen, Kenneth C.; Sampat, Bhaven N.
picture_as_pdf
Balancing innovation and access: India’s pharmaceutical patent laws.
Shadlen, Kenneth C.; Sampat, Bhaven N.; Amin, Tahir M.
picture_as_pdf
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe:lessons for the accelerated approval pathway. (2024)
Shahzad, Mahnum; Naci, Huseyin; Esselen, Katharine M.; Dottino, Joseph A.; Wagner, Anita K.
picture_as_pdf
Beyond polemics: science and ethics of ADHD.
Singh, Ilina
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela, Simiso; Bosch, Bronwyn; Hill, Andrew; Simmons, Bryony; Woods, Joana; Johnstone, Hilary; Akpomiemie, Godspower; Ellis, Leah; Owen, Andrew; Casas, Carmen Perez; Venter, Willem Daniel Francois
picture_as_pdf
Evidence of comparative efficacy should have a formal role in European drug approvals.
Sorenson, Corinna; Naci, Huseyin; Cylus, Jonathan; Mossialos, Elias
The cognitive footprint of medication:a review of cognitive assessments in clinical trials.
Stoner, Charlotte R; Knapp, Martin; Luyten, Jeroen; Kung, Claryn; Richards, Marcus; Rossor, Martin
picture_as_pdf
Health effects associated with Kratom (Mitragyna speciosa) and polysubstance use:a narrative review. (2022)
Striley, Catherine W.; Hoeflich, Carolin C.; Viegas, Andrew T.; Berkowitz, Lindsey A.; Matthews, Emily G.; Akin, Leyla P.; Iheanyi-Okeahialam, Chidinma; Mansoor, Urmeen; McCurdy, Christopher R.
picture_as_pdf
Medicare drug price negotiation in the United States:implications and unanswered questions. (2023)
Sullivan, Sean D.
Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.
Sullivan, Sean D.; Chaturvedi, Shruti; Gautam, Preety; Arnaud, Alix
Has the Centers for Medicare & Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations?
Sullivan, Sean D.; Hernandez, Inmaculada; Ramsey, Scott D.; Neumann, Peter J.
Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze, Simon; Patel, Anita; Kerwin, Robert W; Knapp, Martin; Travis, Michael J
T
A systematic review of nudge interventions to optimize medication prescribing.
Talat, Usman; Schmidtke, Kelly Ann; Khanal, Saval; Chan, Amy; Turner, Alice; Horne, Robert; Chadborn, Tim; Gold, Natalie; Sallis, Anna; Vlaev, Ivo
picture_as_pdf
Relative impact of diagnosis and clinical stage on response to electroconvulsive therapy:a retrospective cohort.
Tedeschi, Eduardo; Hoffmann, Mauricio Scopel; Magalhaes, Pedro V. S.
picture_as_pdf
Moderating effects of diagnosis and gender on the influence of age on electroconvulsive therapy outcome.
Tedeschi, Eduardo; Hoffmann, Mauricio S.; Magalhães, Pedro V.S.
picture_as_pdf
Quantifying preference in drug benefit-risk decisions.
Tervonen, Tommi; Angelis, Aris; Hockley, Kimberley; Pignatti, Francesco; Phillips, Lawrence D.
picture_as_pdf
Quantitative bias analysis for external control arms using real-world data in clinical trials:a primer for clinical researchers. (2024)
Thorlund, Kristian; Duffield, Stephen; Popat, Sanjay; Ramagopalan, Sreeram; Gupta, Alind; Hsu, Grace; Arora, Paul; Subbiah, Vivek
picture_as_pdf
Menopausa e terapia ormonale sostitutiva: qualità di vita e farmacoeconomia.
Tinelli, Michela
Progetto pilota per la rilevazione delle prescrizioni farmaceutiche in Farmacia.
Tinelli, Michela
Development, validation and application of a patient satisfaction scale for a community pharmacy medicines-management service.
Tinelli, Michela; Blenkinsopp, Alison; Bond, Christine
Economic evaluation of anti-epileptic medicines for autistic children with epilepsy. (2023)
Tinelli, Michela; Roddy, Áine; Knapp, Martin; Arango, Celso; Mendez, Maria Andreina; Henderson, Catherine; Murphy, Declan; Canitano, Roberto; Oakley, Bethany; Quoidbach, Vinciane
picture_as_pdf
Measuring value: pharmacoeconomics theory and practice.
Towse, A; Drummond, Michael; Sorenson, Corinna
Measuring value: pharmacoeconomics in theory and practice.
Towse, Adrian; Drummond, Michael; Sorenson, Corinna
Clinical, ethical, and socioeconomic considerations for prescription drug use during pregnancy in women suffering from chronic diseases.
Tzouma, Victoria; Grepstad, Mari; Grimaccia, Federico; Kanavos, Panos
V
Comparing antibiotic prescribing between clinicians in UK primary care:an analysis in a cohort study of eight different measures of antibiotic prescribing.
Van Staa, Tjeerd; Li, Yan; Gold, Natalie; Chadborn, Tim; Welfare, William; Palin, Victoria; Ashcroft, Darren M.; Bircher, Joanna
picture_as_pdf
Therapeutic substitution post-patent expiry: the cases of ace inhibitors and proton pump inhibitors.
Vandoros, Sotiris
The generics paradox revisited: empirical evidence from regulated markets.
Vandoros, Sotiris; Kanavos, Panos
Reforms in the Greek pharmaceutical market during the financial crisis.
Vandoros, Sotiris; Stargardt, Tom
Does adoption of pharmaceutical innovation respond to changes in the regulatory environment?
Varol, Nebibe; Costa-Font, Joan; McGuire, Alistair
Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis.
Vermersch, Patrick; Martinelli, Vittorio; Pfleger, Claudia; Rieckmann, Peter; Alonso-Magdalena, Lucia; Galazka, Andrew; Dangond, Fernando; Phillips, Lawrence D.
picture_as_pdf
Expedited approvals and adverse drug reactions in women.
Viehbeck, Constance
picture_as_pdf
Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis:HTA evidence from seven OECD countries.
Visintin, Erica; Tinelli, Michela; Kanavos, Panos
Price changes and within-class competition of cancer drugs in the USA and Europe:a comparative analysis. (2022)
Vokinger, Kerstin N.; Hwang, Thomas J.; Carl, David L.; Laube, Yannic; Ludwig, Wolf Dieter; Naci, Huseyin; Kesselheim, Aaron S.
Negotiating drug prices in the US - lessons from Europe.
Vokinger, Kerstin N.; Naci, Huseyin
picture_as_pdf
Investments in research and development for supplemental drug indications:implications for drug price negotiations. (2023)
Vokinger, Kerstin N.; Perényi, Gellért; Wouters, Olivier J.
picture_as_pdf
Decision making under uncertainty:comparing regulatory and health technology assessment reviews of medicines in the United States and Europe.
Vreman, Rick A.; Naci, Huseyin; Goettsch, Wim G.; Mantel-Teeuwisse, Aukje K.; Schneeweiss, Sebastian G.; Leufkens, Hubert G.M.; Kesselheim, Aaron S.
picture_as_pdf
W
The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation.
Wallach, Joshua D.; Ross, Joseph S.; Naci, Huseyin
Long read review: drug dealer, MD: how doctors were duped, patients got hooked and why it’s so hard to stop by Anna Lembke.
Williams, Thomas Christie
Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. (2022)
Wouters, Olivier J.; Berenbrok, Lucas A.; He, Meiqi; Li, Yihan; Hernandez, Inmaculada
picture_as_pdf
Product hopping in the drug industry — lessons from Albuterol. (2022)
Wouters, Olivier J.; Feldman, William B.; Tu, S. Sean
picture_as_pdf
Comparing generic drug markets in Europe and the United States:prices, volumes, and spending.
Wouters, Olivier J.; Kanavos, Panos; McKee, Martin
Research and development costs of new drugs:in reply.
Wouters, Olivier J.; McKee, Martin; Luyten, Jeroen
Early chronic kidney disease: diagnosis, management and models of care.
Wouters, Olivier J.; O'Donoghue, Donal J.; Ritchie, James; Kanavos, Panos; Narva, Andrew S.
Z
Medical cannabis for severe treatment resistant epilepsy in children:a case-series of 10 patients.
Zafar, Rayyan; Schlag, Anne; Phillips, Lawrence; Nutt, David J.
picture_as_pdf
HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA.
Zaitceva, V; Tan, I; Mills, M.; Kanavos, P.
Strength of evidence supporting cancer drug approvals in China, 2017-2021.
Zhang, Yichen; Chen, Dingyi; Fu, Mengyuan; Shi, Luwen; Naci, Huseyin; Wagner, Anita Katharina; Ross, Joseph S.; Guan, Xiaodong
Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022)
Zhang, Yichen; Naci, Huseyin; Wagner, Anita K.; Xu, Ziyue; Yang, Yu; Zhu, Jun; Ji, Jiafu; Shi, Luwen; Guan, Xiaodong
picture_as_pdf
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021.
Zhou, Yue; Naci, Huseyin; Chen, Dingyi; Bai, Lin; Shi, Luwen; Guan, Xiaodong; Wagner, Anita Katharina
picture_as_pdf
HPR240 A rapid review of key challenges and success factors in implementing managed entry agreements for pharmaceuticals:lessons for Greece.
Zisis, K.; Karampli, E.; Nomikos, N.; Agorastos, I; Naoum, P.; Tsiantou, V; Kyriopoulos, I; Pavi, E.